Abstract: The present invention relates to novel strains of microorganisms with oxygen-regulated metabolism. The microorganisms have higher growth rates and are more efficient than parental strains. The microorganisms may be used to produce a variety of products of interests, such as recombinant proteins, nucleic acids, such as DNA, amino acids, and chemicals.

Abstract: Reduced genome bacteria with improved genetic stability are provided. Also provided are methods of producing polypeptides using the reduced genome bacteria with improved genetic stability.

Abstract: The present invention relates generally to compositions and methods useful for, inter alia, production of commercial biologic products such as amino acids. More specifically, the present invention relates to genetically modified strains of microorganisms and the use thereof for the production of commercial products. The present invention also provides, inter alia, novel isolated DNA, nucleic acid, vectors and reduced genome bacteria.

Abstract: Reduced genome strains of E. coli MG1 655 are described. In various embodiments, the strains have one or more of equal or improved growth rate, transformation efficiency, protein expression, DNA production, DNA yield and/or DNA quality compared to the parental strain and commercially available strains.

Abstract: Reduced genome strains of E. coli MG1655 are described. In various embodiments, the strains have one or more of equal or improved growth rate, transformation efficiency, protein expression, DNA production, DNA yield and/or DNA quality compared to the parental strain and commercially available strains.

Abstract: Methods for prophylaxis or treatment of sepsis in a subject are provided comprising administering to the subject a therapeutically effective dose of multiple deletion strain bacteria.

Abstract: Methods for prophylaxis or treatment of sepsis in a subject are provided comprising administering to the subject a therapeutically effective dose of multiple deletion strain bacteria.

Abstract: The invention relates to host cells with improved protein expressed properties. The host cells comprise rare tRNA genes within the one or more rRNA operons.

Abstract: Methods for introducing and expressing genes in animal cells are provided comprising infecting the animal cells with live invasive reduced-genome bacteria comprising a eukaryotic expression cassette comprising said gene. Also provided are methods for producing a pluripotent stem (iPS) cell from a mammalian somatic cell comprising infecting the somatic cell with live invasive reduced-genome bacteria comprising one or more eukaryotic expression cassettes comprising at least a gene encoding the transcription factor Oct3/4 and a gene encoding a member of the SRY-related HMG-box (Sox) transcription factor family.

Abstract: The various embodiments of the present invention relate generally to plasmid DNA preparations and to methods for producing and using such preparations.

Abstract: Provided herein is a nucleic acid comprising a mutant lac operator operably linked to a gene of interest, a host cell comprising the nucleic acid, and a method of using the host cell to express the gene of interest. Also provided is a recA-mediated cloning method.

Abstract: The present invention relates generally to compositions and methods useful for, inter alia, production of commercial biologic products such as amino acids. More specifically, the present invention relates to genetically modified strains of microorganisms and the use thereof for the production of commercial products. The present invention also provides, inter alia, novel isolated DNA, nucleic acid, vectors and reduced genome bacteria.

Abstract: The various embodiments of the present invention relate generally to plasmid DNA preparations and to methods for producing and using such preparations.

Abstract: The present invention relates to novel strains of microorganisms with oxygen-regulated metabolism. The microorganisms have higher growth rates and are more efficient than parental strains. The microorganisms may be used to produce a variety of products of interests, such as recombinant proteins, nucleic acids, such as DNA, amino acids, and chemicals.

Abstract: The present invention discloses that a bacterium having a genome that is genetically engineered to be at least 10% smaller than the genome of its native parent strain has better transformation competence. Specific E. coli strains, having significantly reduced genome sizes, are disclosed which are highly transformation competent. A medium and methodology is taught which enables transformation efficiencies to be increased further.